QuintilesIMS Wins Society for Clinical Research Sites’ 2016 Eagle Award
QuintilesIMS (NYSE:Q) announced today that it has been awarded the 2016 Eagle Award from the Society for Clinical Research Sites (SCRS) for the fourth consecutive year. Presented during the annual SCRS Site Solutions Summit, the site-nominated award recognizes contract research organizations (CRO) and biopharmaceutical sponsors dedicated to building positive relationships with research sites through leadership, professionalism and integrity.
“We are honored to bring this award home again by focusing on what really matters to sites,” said Cynthia Verst, president, Clinical Operations at QuintilesIMS. “This award once again recognizes our focus on enhancing our site relationships and delivering best-in-class site facing operations. I would like to thank our talented teams, as well as the sites and clients with whom we partner, for their support as we work together to help our customers drive healthcare forward.”
"QuintilesIMS' commitment to site relationships has been demonstrated in their repeated placement as a finalist or winner of the CRO Eagle Award," said Christine Pierre, president of SCRS. "The bar continues to rise as CROs develop processes that support site sustainability and we applaud all of the Eagle Award finalists."
In advance of the Site Solutions Summit, SCRS members and clinical research site professionals globally were invited to vote for the CRO and sponsor they felt demonstrated a strong commitment to site partnerships. Criteria also considered for this award included patient safety, timely enrollment and effective communication to optimize study success.
For more information about the SCRS Eagle Award, visit http://sitesolutionssummit.com/eagle-awards/ .
QuintilesIMS (NYSE:Q) is a leading integrated information and technology-enabled healthcare service provider worldwide, dedicated to helping its clients improve their clinical, scientific and commercial results. Formed through the merger of Quintiles and IMS Health, QuintilesIMS’s approximately 50,000 employees conduct operations in more than 100 countries. Companies seeking to improve real-world patient outcomes and enhanced clinical trial outsourcing through treatment innovations, care provision and access can leverage QuintilesIMS’s broad range of healthcare information, technology and service solutions to drive new insights and approaches. QuintilesIMS provides solutions that span clinical to commercial bringing clients a unique opportunity to realize the full potential of innovations and advance healthcare outcomes.
As a global leader in protecting individual patient privacy, QuintilesIMS uses healthcare data to deliver critical, real-world disease and treatment insights. Through a wide variety of privacy-enhancing technologies and safeguards, QuintilesIMS protects individual privacy while managing information to drive healthcare forward. These insights and execution capabilities help biotech, medical device, and pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders in the development and approval of new therapies, identify unmet treatment needs and understand the safety, effectiveness and value of pharmaceutical products in improving overall health outcomes. To learn more, visit www.QuintilesIMS.com .
Quintiles Media Relations
Phil Bridges, +1-919-998-1653 (office)
QuintilesIMS Media Relations
Tor Constantino, +1-484-567-6732
QuintilesIMS, Investor Relations
Tom Kinsley, +1-203-448-4691
Quintiles Investor Relations
Todd Kasper, +1-919-998-2590
Information om Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Følg pressemeddelelser fra Business Wire
Skrive dig op her og du vil løbende modtage pressemeddelelser på mail. Indtast din mail, klik på abonner og følg instruktionerne i den udsendte mail.
Flere pressemeddelelser fra Business Wire
ADC-THERAPEUTICS11.12.2017 07:32 | pressemeddelelse
ADC Therapeutics Announces Interim Phase I Data from its Novel Antibody-Drug Conjugate ADCT-301
ADC-THERAPEUTICS11.12.2017 07:02 | pressemeddelelse
ADC Therapeutics Presents Interim Phase I Data from its Novel Antibody-Drug Conjugate ADCT-402
FL-GA-TELESIS11.12.2017 06:03 | pressemeddelelse
GA Telesis Launches Leveraged Finance Group with the Appointments of David Lloyd and Nolan Heske
ASTRAZENECA10.12.2017 23:47 | pressemeddelelse
AstraZeneca’s Calquence (acalabrutinib) Shows Potential in Chronic Lymphocytic Leukaemia Trials
NJ-CELGENE/BLUEBIRD-BIO10.12.2017 16:32 | pressemeddelelse
Celgene Corporation and bluebird bio Announce Updated Results from Ongoing Multicenter Phase 1 Study of bb2121 Anti-BCMA CAR T Cell Therapy in Patients with Late Stage Relapsed/Refractory Multiple Myeloma at ASH Annual Meeting
GA-GILEAD-SCIENCES/KITE10.12.2017 16:32 | pressemeddelelse
Kite Announces Long-Term Data From Pivotal ZUMA-1 Study of Yescarta™ (Axicabtagene Ciloleucel) in Patients With Refractory Large B-cell Lymphoma
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter, og finde vores kontaktoplysninger.Besøg vores nyhedsrum